Search results

Skip to results

Type

Status

Last updated

Showing 1 to 15 of 17 results for liraglutide

  1. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

  2. Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)

    NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission.

    Sections for TA749

  3. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

    This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.

  4. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

    Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

  5. Semaglutide for managing overweight and obesity (TA875)

    Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.

  6. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....

  7. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

  8. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

  9. Tirzepatide for treating type 2 diabetes (TA924)

    Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.

  10. Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.

  11. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

  12. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

  13. Insulin icodec for treating type 2 diabetes [ID6175]

    In development [GID-TA11104] Expected publication date: TBC

  14. New treatment option recommended for people with type 2 diabetes

    Around 180,000 people with difficult to manage type 2 diabetes could benefit from tirzepatide as new treatment option for type 2 diabetes.

  15. Digital services to enable easier access to weight management support

    Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England